Atsushi Yasumoto
Division of Laboratory and Transfusion Medicine, Hokkaido University Hospital.
Rinsho Ketsueki. 2022;63(9):1233-1241. doi: 10.11406/rinketsu.63.1233.
The levels of anti-platelet factor 4 (PF4) antibodies, also known as anti-PF4 or heparin complex antibodies, are used to diagnose heparin-induced thrombocytopenia (HIT). In HIT, anti-PF4 antibodies induced by heparin exposure cause thrombocytopenia and thrombosis. However, anti-PF4 antibodies were recently reported to be associated with the development of fatal vaccine-induced immune thrombotic thrombocytopenia (VITT) after adenoviral vector vaccination for coronavirus disease 2019. HIT and VITT are caused by anti-PF4 antibodies and have similar pathological conditions. However, the severity of these conditions differs and the detection sensitivity of their antibodies varies depending on the assays used. Herein, we review HIT and VITT associated with anti-PF4 antibodies.
抗血小板因子4（PF4）抗体水平，也称为抗PF4或肝素复合物抗体，用于诊断肝素诱导的血小板减少症（HIT）。在HIT中，肝素暴露诱导的抗PF4抗体导致血小板减少和血栓形成。然而，最近有报道称，抗PF4抗体与2019冠状病毒病腺病毒载体疫苗接种后发生的致命性疫苗诱导的免疫性血栓性血小板减少症（VITT）有关。HIT和VITT均由抗PF4抗体引起，且病理状况相似。然而，这些病症的严重程度不同，其抗体的检测灵敏度也因所使用的检测方法而异。在此，我们综述与抗PF4抗体相关的HIT和VITT。
